The New Zealand medical journal · 1991
Trial of slow release diltiazem for essential hypertension in general practice.
Клиническое исследованиеКонтролируемое клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Coulter D M
Аннотация
In New Zealand diltiazem has been approved since 1984 for the treatment of angina pectoris and was available only as short acting tablets. This study was a trial of a slow release formulation in the treatment of hypertension. A single blind placebo controlled study was undertaken on 24 patients in general practice using a once daily dose with a maximum of 360 mg. The mean fall in resting supine diastolic blood pressure was 17.3 mmHg, 95% CI 14.4 to 20.2; t = 12.2, df = 23, p = 0.0001. Twelve patients (50%) achieved a fall in diastolic pressure to 90 mmHg or less with the minimum dose (120 mg) while 19 patients (79%) achieved this level with up to 360 mg daily and 22 patients (92%) had a fall of diastolic pressure of 10 mmHg or more. One patient was withdrawn because of a rash. Other adverse reactions were mild and usually tolerable.